Literature DB >> 8586496

Systemic lupus erythematosus with choroidopathy and serous retinal detachment.

D Hannouche1, J F Korobelnik, I Cochereau, G Hayem, J Beaudreuil, O Meyer, T Hoang-Xuan.   

Abstract

Systemic lupus erythematosus associated ocular manifestations usually consist of cotton-wool spots and retinal hemorrhages. The authors report one case of lupus choroidopathy revealed by bilateral serous retinal detachment, occurring 4 months after a systemic flare-up of the disease. An immune complexes-mediated phenomenon is involved in these manifestations, which are usually controlled by systemic corticosteroids and immunosuppressive agents. Plasma exchanges were successfully applied in this case, resulting in a disappearance of the retinal detachment in one month.

Entities:  

Mesh:

Year:  1995        PMID: 8586496     DOI: 10.1007/bf00133184

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  6 in total

1.  Choroidopathy in systemic lupus erythematosus.

Authors:  D A Jabs; A M Hanneken; A P Schachat; S L Fine
Journal:  Arch Ophthalmol       Date:  1988-02

2.  Visual loss from central serous retinopathy in systemic lupus erythematosus.

Authors:  M B Eckstein; D J Spalton; G Holder
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

3.  Choroiditis in systemic lupus erythematosus.

Authors:  M T Carpenter; J E O'Boyle; R W Enzenauer; R J Enzenauer; W J Waterhouse
Journal:  Am J Ophthalmol       Date:  1994-04-15       Impact factor: 5.258

4.  Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus.

Authors:  T Matsuo; T Nakayama; T Koyama; N Matsuo
Journal:  Ophthalmologica       Date:  1987       Impact factor: 3.250

5.  Fundus lesions in malignant hypertension. VI. Hypertensive choroidopathy.

Authors:  S S Hayreh; G E Servais; P S Virdi
Journal:  Ophthalmology       Date:  1986-11       Impact factor: 12.079

6.  Plasma exchange in systemic lupus erythematosus. Experience in thirty-seven patients.

Authors:  R Lombardo; F Cepparrone; G Di Pietro; C Franco; G Graziani; G Avanzi
Journal:  Int J Artif Organs       Date:  1993-12       Impact factor: 1.595

  6 in total
  8 in total

1.  Acute lupus choroidopathy: multimodal imaging and differential diagnosis from central serous chorioretinopathy.

Authors:  Murat Hasanreisoglu; Gokcen D Gulpinar Ikiz; Hamit Kucuk; Ozkan Varan; Sengul Ozdek
Journal:  Int Ophthalmol       Date:  2017-01-03       Impact factor: 2.031

2.  Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach.

Authors:  Ren Liu; Yan Wang; Qiang Xia; Tian Xu; Ting Han; Shuang Cai; Shui-Lin Luo; Rui Wu; Yi Shao
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 3.  Current perspectives on ophthalmic manifestations of childhood rheumatic diseases.

Authors:  Neal V Palejwala; Steven Yeh; Sheila T Angeles-Han
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

4.  Ocular manifestations of systemic lupus erythematosus: a review of the literature.

Authors:  Neal V Palejwala; Harpreet S Walia; Steven Yeh
Journal:  Autoimmune Dis       Date:  2012-07-02

Review 5.  Choroidal involvement in systemic vasculitis: a systematic review.

Authors:  Pınar Çakar Özdal; Ilknur Tugal-Tutkun
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-04-04

6.  Choroidopathy and kidney disease: a case report and review of the literature.

Authors:  Nirav V Kamdar; Amsalu Erko; Jason S Ehrlich; Jonathan W Kim; Neeraja Kambham; Glenn M Chertow
Journal:  Cases J       Date:  2009-05-12

7.  [Choroidopathy of systemic lupus erythematosus: about a case].

Authors:  Benatiya Andaloussi Idriss; Chraibi Fouad; Bhallil Salima; Abdellaoui Meryem; Tahri Hicham
Journal:  Pan Afr Med J       Date:  2013-03-28

8.  Central serous chorioretinopathy and systemic corticosteroids in rheumatic diseases: report of three cases.

Authors:  Elia Valls Pascual; Lucía Martínez-Costa; Fernando Santander
Journal:  BMC Musculoskelet Disord       Date:  2015-12-05       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.